This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (311) Diabetes (187) Pilot studies (non-ehealth) (65) Chronic Conditions (270)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/56067, first published .
Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)

Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)

Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)

Authors of this article:

Steffen Flindt Nielsen1, 2 Author Orcid Image ;   Camilla Lundgreen Duus1, 2 Author Orcid Image ;   Niels Henrik Buus2, 3 Author Orcid Image ;   Jesper Nørgaard Bech1, 2 Author Orcid Image ;   Frank Holden Mose1, 2 Author Orcid Image
Article Authors Cited by (2) Tweetations (3) Metrics

Altmetric

Altmetric discovers Social Media mentions. Click the ‘See more details’ link for a full report.

Dimensions

Dimensions discovers Citations. Click the ‘details’ link for a full report.

Metrics Since Publication

Download .csv
Daily | Monthly | Annually